Clinical trials: Renal Cell Cancer Metastatic
Non-Small Cell Lung Cancer, Malignant Melanoma
Phase Ib of L-NMMA and Pembrolizumab
The purpose of this Phase Ib study is to test the safety of NG-monomethyl-L-arginine (L-NMMA) and pembrolizumab when used together in participants with melanoma, non-small cell lung cancer (NSCLC), head and neck squamous cell…
- Conditions
- Non-Small Cell Lung Cancer, Malignant Melanoma, Head and Neck Squamous Cell Carcinoma, Classical Hodgkin Lymphoma
- Trial name
- NCT03236935
- Testing
- L-NMMA, Pembrolizumab
- Where
- United States
- Volunteers
- 12 people
- Sponsor
- The Methodist Hospital Research Institute
Locally Advanced Bladder Urothelial Carcinoma, Locally Advanced Renal Pelvis Urothelial Carcinoma
Atezolizumab With or Without Eribulin Mesylate in Treating Patients With Recurrent Locally Advanced or Metastatic Urothelial Cancer
This phase II trial studies the side effects of atezolizumab with or without eribulin mesylate and how well they work in treating patients with urothelial cancer that has come back (recurrent), spread to nearby tissues or lymph…
- Conditions
- Locally Advanced Bladder Urothelial Carcinoma, Locally Advanced Renal Pelvis Urothelial Carcinoma, Locally Advanced Ureter Urothelial Carcinoma, Locally Advanced Urethral Urothelial Carcinoma
- Trial name
- NCT03237780
- Testing
- Atezolizumab, Biopsy Procedure, Biospecimen Collection
- Where
- 21 sites in United States
- Volunteers
- 72 people
- Sponsor
- National Cancer Institute (NCI)
Advanced Cancer, Advanced Solid Tumor
A Study of Oral 7HP349 (Alintegimod) in Combination With Ipilimumab Followed by Nivolumab Monotherapy
This study is an open-label Phase Ib (Part A) dose escalation followed by a blinded, randomized, multi cohort Phase 2a (Part B) comparison of combination vs. reference regimens.
- Conditions
- Advanced Cancer, Advanced Solid Tumor, Melanoma, Metastasis
- Trial name
- NCT06362369
- Testing
- Alintegimod, Ipilimumab, Nivolumab
- Where
- 5 sites in United States
- Volunteers
- 126 people
- Sponsor
- 7 Hills Pharma, LLC
Estrogen Receptor Negative, Head and Neck Squamous Cell Carcinoma
Talazoparib in Treating Patients With Advanced or Metastatic Solid Tumors That Cannot Be Removed by Surgery and Liver or Kidney Dysfunction
This phase I trial studies the side effects and best dose of talazoparib in treating patients with solid tumors that have spread to other places in the body and usually cannot be cured or controlled with treatment (advanced) or…
- Conditions
- Estrogen Receptor Negative, Head and Neck Squamous Cell Carcinoma, HER2/Neu Negative, Hormone-Resistant Prostate Cancer
- Trial name
- NCT02567396
- Testing
- Laboratory Biomarker Analysis, Pharmacological Study, Talazoparib
- Sponsor
- National Cancer Institute (NCI)
Renal Cancer Metastatic
CLARA: Somatic and Germline Mechanisms That Impact Renal Cancer Immunotherapy
The study is studying the joint contribution and interactions of germline variants and somatic mutations and their impact on Renal Cell Carcinoma (RCC) development and treatment (immunotherapy).
- Trial name
- NCT05215470
- Testing
- Nivolumab, Ipilimumab
- Where
- Brazil
- Volunteers
- 100 people
- Sponsor
- Hospital das Clínicas de Ribeirão Preto
Metastatic Renal Cell Carcinoma, Genitourinary Cancer (Bladder, Prostate or Testicular)
RNA Extraction and Amplification From Biopsy Specimens in Subjects With Metastatic Renal Cell Carcinoma (AGS-NTS-017)
The primary objective is to evaluate methods for AGS-003 production from surgical (stage I) and metastatic biopsy (stage II) Renal Cell Carcinoma (RCC) and a small subset of other GU cancers (expansion cohort) specimens using…
- Trial name
- NCT02026960
- Testing
- RNA extraction and amplification from biopsy specimens
- Where
- United States
- Volunteers
- 14 people
- Sponsor
- Duke University
Metastatic Renal Cell Carcinoma, Stage III Renal Cell Cancer AJCC v8
A Study to Compare Treatments for a Type of Kidney Cancer Called TFE/Translocation Renal Cell Carcinoma (tRCC)
This phase II trial studies how well axitinib and nivolumab work in treating patients with TFE/translocation renal cell carcinoma that cannot be removed by surgery (unresectable) or has spread to other places in the body…
- Conditions
- Metastatic Renal Cell Carcinoma, Stage III Renal Cell Cancer AJCC v8, Stage IV Renal Cell Cancer AJCC v8, TFE3-Rearranged Renal Cell Carcinoma
- Trial name
- NCT03595124
- Testing
- Axitinib, Nivolumab
- Where
- 267 sites in United States, Puerto Rico
- Volunteers
- 15 people
- Sponsor
- National Cancer Institute (NCI)
Clinical Stage III Cutaneous Melanoma AJCC v8, Clinical Stage IV Cutaneous Melanoma AJCC v8
Diet and Immune Effects Trial: DIET- A Randomized Double Blinded Dietary Intervention Study in Patients With Metastatic Melanoma Receiving Immunotherapy
This is a randomized, double-blind, fully controlled feeding study that will enroll melanoma patients starting standard-of-care ICB in three settings: adjuvant, neoadjuvant, and unresectable.
- Conditions
- Clinical Stage III Cutaneous Melanoma AJCC v8, Clinical Stage IV Cutaneous Melanoma AJCC v8, Metastatic Melanoma, Pathologic Stage III Cutaneous Melanoma AJCC v8
- Trial name
- DIET (NCT04645680)
- Testing
- Dietary Intervention, Quality-of-Life Assessment, Questionnaire Administration
- Where
- United States
- Volunteers
- 50 people
- Sponsor
- M.D. Anderson Cancer Center
Renal Cancer, Melanoma
Interleukin-2 With Sorafenib (BAY 43-9006) for Unresectable or Metastatic Clear Cell Renal Carcinoma (RCC) and Metastatic Melanoma
The primary objective of this study will be to determine the toxicity and Maximum Tolerated Dose (MTD) of the combination of high dose aldesleukin and sorafenib in previously untreated patients with metastatic or unresectable…
- Trial name
- NCT00418496
- Testing
- Aldesleukin, Sorafenib
- Where
- United States
- Volunteers
- 17 people
- Sponsor
- Ohio State University Comprehensive Cancer Center
Metastatic Renal Cell Carcinoma (mRCC)
Clinical Outcomes For Patients With Metastatic Renal Cell Carcinoma (mRCC) Who Received Sunitinib After 1st Line Immune-oncology (IO) Treatments
The study aims to assess clinical outcomes in mRCC patients treated with sunitinib in second-line following IO therapy in real world clinical practices.
- Trial name
- NCT04175262
- Testing
- sunitinib
- Where
- Canada
- Volunteers
- 102 people
- Sponsor
- Pfizer
Breast Cancer, Chronic Myeloproliferative Disorders
Beclomethasone in Treating Patients With Graft-Versus-Host Disease of the Esophagus, Stomach, Small Intestine, or Colon
RATIONALE: Beclomethasone may be an effective treatment for graft-versus-host disease. PURPOSE: Phase I/II trial to study the effectiveness of beclomethasone in treating patients who have graft-versus-host disease of the…
- Conditions
- Breast Cancer, Chronic Myeloproliferative Disorders, Gestational Trophoblastic Tumor, Graft Versus Host Disease
- Trial name
- NCT00010283
- Testing
- beclomethasone dipropionate
- Where
- United States
- Sponsor
- Fred Hutchinson Cancer Center
Carcinoma, Renal Cell
Substudy 03A: A Study of Immune and Targeted Combination Therapies in Participants With First Line (1L) Renal Cell Carcinoma (MK-3475-03A)
Substudy 03A is part of a larger research study that is testing experimental treatments for renal cell carcinoma (RCC). The larger study is the umbrella study (U03).
- Trial name
- NCT04626479
- Testing
- Pembrolizumab, Favezelimab/Pembrolizumab, Belzutifan
- Where
- 55 sites in United States, Australia and 12 more
- Volunteers
- 393 people
- Sponsor
- Merck Sharp & Dohme LLC
Kidney Cancer
Sorafenib in Treating Patients With Metastatic or Unresectable Kidney Cancer
RATIONALE: Sorafenib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth and by blocking blood flow to the tumor.
- Trial name
- NCT00496756
- Testing
- Sorafenib
- Where
- United States
- Volunteers
- 14 people
- Sponsor
- University of Nebraska
Locally Metastatic Malignant Neoplasm
Everolimus/Sorafenib or Sunitinib in Patients With Metastatic Renal Cell Carcinoma (RCC)
This is a phase II trial that follows the completion of the phase I UCSF trial of everolimus and sorafenib for Renal Cell Carcinoma (RCC). This trial will be for patients who have not had treatment for RCC before.
- Trial name
- NCT01616186
- Testing
- Everolimus and sorafenib, Sunitinib monotherapy
- Sponsor
- Andrea Harzstark
Metastatic Renal Cell Carcinoma
Phase II Study of Sunitinib Rechallenge in Patients With Metastatic Renal Cell Carcinoma
Targeted therapies are associated with (acquired) resistance after a median of 5-11 months of treatment, resulting in disease progression, while almost no tumors are intrinsically resistant in the first line setting.
- Trial name
- NCT02071641
- Testing
- Sunitinib
- Where
- Netherlands
- Volunteers
- 5 people
- Sponsor
- Amsterdam UMC, location VUmc
Renal Cell Carcinoma
Duration of Treatment With Tyrosine Kinase Inhibitors in the Treatment of Metastatic Renal Cell Carcinoma
This study is a prospective, non-interventional, non-controlled, multi-center, observational cohort study. The medication is prescribed within the regular practice of the physician.
- Trial name
- TURCOS (NCT01585974)
- Testing
- No intervention
- Where
- Turkey (Türkiye)
- Volunteers
- 151 people
- Sponsor
- Bayer
Urothelial Cancer, Metastatic Urothelial Carcinoma
Sacituzumab Govitecan Plus EV in Metastatic UC
Phase I of this research study will assess what doses of Sacituzumab Govitecan and Enfortumab Vedotin can be safely combined in the treatment of metastatic urothelial carcinoma (mUC).
- Conditions
- Urothelial Cancer, Metastatic Urothelial Carcinoma, Metastatic Urothelial Carcinoma of the Renal Pelvis and Ureter, Bladder Cancer
- Trial name
- NCT04724018
- Testing
- Sacituzumab Govitecan (SG), Enfortumab vedotin-ejfv (EV), Pembrolizumab
- Where
- United States
- Volunteers
- 106 people
- Sponsor
- Dana-Farber Cancer Institute
Cancer
Laboratory Assay in Determining Cancer Resistance in Patients With Metastatic Cancer and in Healthy Participants
RATIONALE: Studying samples of blood and tissue in the laboratory from patients with cancer and from healthy participants may help doctors learn more about cancer.
- Trial name
- NCT00899496
- Testing
- immunological diagnostic method, physiologic testing
- Where
- United States
- Volunteers
- 54 people, healthy volunteers welcome
- Sponsor
- Wake Forest University Health Sciences
Melanoma, Metastatic Kidney Cancer
Trial of Outpatient Intravenous Interleukin-2 in Malignant Melanoma and Metastatic Kidney Cancer
The current study will test single agent IL-2 in stage IV melanoma and kidney cancer.
- Trial name
- NCT01355562
- Testing
- Interleukin-2 (IL-2)
- Where
- 2 sites in United States
- Sponsor
- Loma Linda University
Metastatic Renal Cell Carcinoma
PD-1 Knockout Engineered T Cells for Metastatic Renal Cell Carcinoma.
This study will evaluate the safety of PD-1 knockout engineered T cells in treating metastatic advanced renal cancer. Blood samples will also be collected for research purposes.
- Trial name
- NCT02867332
- Testing
- PD-1 Knockout T Cells, Cyclophosphamide, IL-2
- Sponsor
- Peking University
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.